Paper Details

  1. Home
  2. Paper Details

Second-Degree Type 2 Atrioventricular Block Requiring Permanent Cardiac Pacing in Patients on CDK4/6 Inhibitors: Report of Two Cases.

Author: CiciniMaria Paola, CognettiFrancesco, FerrettiGianluigi, MoraceNicola, NisticòCecilia, RulliFrancesco

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

CDK4/6Is are a type of cancer drug used to treat breast cancer. While they have been shown to be effective, they can also cause heart problems. However, the risk of developing these heart issues is relatively low.
Paper Details　
Original Abstract of the Article :
A wide spectrum of cardiovascular (CV) toxicity is associated with anticancer treatment, and nearly all chemotherapeutic agents can elicit CV toxicity. Inhibitors of cyclin-dependent kinases 4/6 (CDK4/6Is) have become standard of care in the treatment of hormone receptor-positive, human epidermal gr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247538/

データ提供：米国国立医学図書館（NLM）

Second-Degree Type 2 Atrioventricular Block Requiring Permanent Cardiac Pacing in Patients on CDK4/6 Inhibitors

CDK4/6 inhibitors are increasingly used to treat certain types of breast cancer, but their potential cardiovascular side effects are still being investigated. This case report describes two patients who developed second-degree type 2 atrioventricular block requiring permanent cardiac pacing after receiving CDK4/6 inhibitors.

Cardiovascular Side Effects of CDK4/6 Inhibitors

This report highlights the importance of monitoring patients receiving CDK4/6 inhibitors for cardiovascular side effects. It underscores the need for vigilance in managing these potentially serious complications.

Further Research Needed

This case report emphasizes the need for further research to fully understand the cardiovascular risks associated with CDK4/6 inhibitors. This is crucial for ensuring the safe and effective use of these drugs in treating breast cancer patients.

Dr. Camel's Conclusion

This case report serves as a reminder that even with advancements in cancer treatment, vigilance is crucial in monitoring for potential side effects. It's like navigating a desert where hidden dangers may lurk beneath the surface. We need to stay informed about the risks associated with new therapies to ensure the safety and well-being of our patients.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-06-02
Further Info :

Pubmed ID

35957944

DOI: Digital Object Identifier

PMC9247538

Related Literature

Article Analysis
・Side Effects of abemaciclib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.